Ranbaxy Buys Biovel For An Entry Into Vaccines and Biotherapeutics
This article was originally published in The Pink Sheet Daily
Executive Summary
Ranbaxy clinched a deal with Bangalore-based Biovel in an asset buyout that is expected to help it gain foothold in a market that reached $700 million in India and $21 billion in worldwide sales in 2008.